EXO Biologics (and its CDMO subsidiary, ExoXpert) has announced it has received Good Manufacturing Practice (GMP) certification for its manufacturing plant in Liège, Belgium. In addition, the company says it has managed to achieve the loading of GMP-grade exosomes with mRNA and DNA payloads, describing it as… Read More
EXO Biologics has completed dosing of the first cohort of patients in its EVENEW study, the first European Medicines Agency (EMA) authorised clinical trial involving mesenchymal stromal cell (MSC)-based exosomes. The Phase I/II clinical trial is testing the company’s lead candidate EXOB-001, developed to prevent bronchopulmonary… Read More
EXO Biologics has launched ExoXpert, a contract development and manufacturing organisation (CDMO) specialising in exosomes which offers a mesenchymal stem cells (MSC)-based exosome manufacturing platform used in European clinical trials. During the development of its lead exosome candidate, EXOB-001, Exo Biologics developed ExoPulse, an industrial exosome manufacturing… Read More
